Alvotech (ALVO) makes biosimilar versions of branded medicines that have gone off-patent. The year 2024 has been transformational for Alvotech as it marked a gradual transition of ALVO from an R&D company into a full-scale global commercial biologic company. The company recently gained approval for some key biosimilar products like AVT04, its biosimilar to J&J’s (JNJ) blockbuster immunology drug, Stelara, and AVT02, its biosimilar to AbbVie’s (ABBV) blockbuster immunology drug Humira. Alvotech has a commerc ...